查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2046578

白蛋白和肌酸酐檢測市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、類型、最終用戶、地區和競爭格局分類，2021-2031年

Albumin & Creatinine Tests Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Type, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球白蛋白和肌酸酐檢測市場預計將從 2025 年的 16.6627 億美元成長到 2031 年的 43.0283 億美元，複合年成長率達到 17.13%。

該市場涵蓋用於定量檢測尿液白蛋白和肌酸酐濃度的診斷儀器、試劑和耗材。這些指標是評估腎小球濾過率和檢測慢性腎臟病的重要生物標記。推動該市場成長的主要因素是全球糖尿病和高血壓等文明病的盛行率不斷上升，這些疾病需要定期監測腎功能以預防併發症。此外，全球人口快速老化（老年人本身更容易出現腎功能損害）以及政府主導的早期預防篩檢項目，都是該市場持續發展的根本驅動力。

市場概覽
預測期 2027-2031
市場規模：2025年 1,666,270,000 美元
市場規模：2031年 43.0283億美元
複合年成長率：2026-2031年 17.13%
成長最快的細分市場 油尺和試劑盒
最大的市場 北美洲

然而，低收入和中等收入國家診斷基礎設施的匱乏和保險報銷的不足是進一步拓展市場的主要障礙，這限制了患者獲得必要的篩檢服務。鑑於腎臟疾病負擔沉重，亟需有效的管理策略，這種服務取得的差距尤其令人擔憂。根據國際腎臟病學會估計，到2024年，全球將有超過8.5億人患有腎臟疾病，這一數據凸顯了擴充性且經濟高效的檢測解決方案的迫切需求，以減輕腎臟疾病對全球健康日益加劇的影響。

市場促進因素

全球慢性腎臟病(CKD) 盛行率的上升以及糖尿病腎臟病變發病率的增加是推動白蛋白和肌酸酐檢測需求成長的主要因素。隨著生活方式的改變導致代謝性疾病發病率的增加，定期監測腎功能以預防不可逆的器官損傷的需求日益成長，尤其是在糖尿病患者中，腎臟病是糖尿病的常見併發症。美國疾病管制與預防中心 (CDC) 於 2024 年 5 月發布的一份報告指出，大約三分之一的糖尿病成人患者可能患有慢性腎臟病，這凸顯了這些疾病之間的顯著相關性以及持續診斷評估的必要性。

同時，即時診斷解決方案的技術進步以及居家預防性健康監測的日益普及正在重塑市場准入格局。諸如基於智慧型手機的尿液檢查和高通量檢測系統等創新技術，透過提供更快、更便捷的替代傳統方法，消除了檢測障礙。例如，Healthy.io 在 2024 年 9 月發布的新聞稿指出，與標準治療相比，使用智慧型手機進行居家白蛋白尿尿液檢查可使慢性腎臟病檢測的依從性提高一倍以上，完成率達到 53.1%。此外，各公司正致力於提升儀器性能，以因應檢測需求的激增。羅氏公司於 2024 年推出的 cobas c 703 分析儀，每小時處理能力高達 2000 次檢測，顯著提高了檢查室效率。

市場挑戰

全球白蛋白和肌酸酐檢測市場成長的主要障礙是醫療基礎設施和報銷模式的巨大差異，尤其是在開發中國家。儘管全球腎臟疾病發生率不斷上升，但中低收入國家的醫療系統無法負擔必要的診斷工具費用，嚴重限制了市場擴張。檢查室能力有限和公共資金不足導致白蛋白和肌酸酐檢測仍然難以普及。因此，高疾病負擔並未轉化為實際檢測，即使在理論上需求潛力最大的地區，市場滲透率也停滯不前。

這種基礎設施的不平衡導致臨床需求與市場收入之間直接脫節。由於缺乏政府主導的篩檢項目或保險覆蓋，定期監測的費用轉嫁給了無力承擔的患者，造成診斷漏報現象普遍存在。根據國際腎臟病學會統計，截至2024年，僅25%的調查對象國家將慢性腎臟病篩檢計畫有效納入國家衛生政策，且獲得必要的尿液白蛋白/肌酸酐比值檢測的機會極為有限。因此，由於這些人口稠密地區缺乏系統性的支持，診斷試劑和耗材的引入受到限制，導致製造商面臨成長停滯的困境。

市場趨勢

將人工智慧 (AI) 引入診斷結果解讀領域，正徹底改變市場格局，其應用範圍已超越簡單的自動化，邁向預測風險分層。與僅依賴目前生物標記值的傳統分析不同，新型 AI 模型整合了縱向臨床數據，能夠以更高的準確率預測腎功能衰退。根據卡內基美隆大學 2025 年 9 月發布的新聞稿，研究人員開發了一種結合電子健康記錄和保險理賠數據的框架，在 24 個月的觀察期內，該框架能夠比標準模型更準確地識別進展至末期腎臟病的患者。

同時，受臨床框架發展趨勢的推動，該框架優先考慮尿液白蛋白/肌酸酐比值（uACR）而非單一蛋白質檢測，市場正經歷著向尿液白蛋白/肌酸酐比值聯合檢測的根本性轉變。全球標準更新後，強制要求採用基於比值的篩檢，以儘早發現傳統方法常忽略的腎功能損害，這進一步加速了這一趨勢。根據日本診斷與臨床檢驗醫學會2025年7月報告，2024年KDIGO指引擴大了篩檢範圍，建議所有高血壓患者應進行uACR檢測。預計該指南將顯著提高uACR檢測在所有臨床環境中的應用率。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球白蛋白和肌酸酐檢測市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品分類（分析儀器、試劑盒、試紙條試劑盒、試劑）
    • 依類型（血液/血清肌酸酐檢測、尿液檢查）
    • 依最終使用者（醫院/診所、病理檢查室、研究機構/實驗室、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美白蛋白和肌酸酐檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲白蛋白和肌酸酐檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區白蛋白和肌酸酐檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲白蛋白和肌酸酐檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美白蛋白與肌酸酐檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球白蛋白和肌酸酐檢測市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Abbott Laboratories Inc
  • Roche Diagnostics Corp
  • Siemens Healthineers AG
  • Danaher Corp
  • Thermo Fisher Scientific Inc
  • Sysmex Corp
  • Ortho-Clinical Diagnostics, Inc.
  • PromoCell GmbH
  • Randox Laboratories Ltd
  • FUJIFILM Wako Pure Chemical Corp

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 19966

The Global Albumin & Creatinine Tests Market is projected to expand from USD 1666.27 Million in 2025 to USD 4302.83 Million by 2031, achieving a CAGR of 17.13%. This market encompasses diagnostic instruments, reagents, and consumables essential for quantifying urine albumin and creatinine levels, which act as critical biomarkers for evaluating glomerular filtration rates and detecting chronic kidney disease. The primary drivers of this growth include the rising global incidence of lifestyle-related conditions like diabetes mellitus and hypertension, which require regular renal function monitoring to prevent complications. Additionally, the rapidly aging global population, which is inherently more prone to renal insufficiency, combined with government-led initiatives to establish early preventive screening programs, serves as a fundamental catalyst for sustained market development.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1666.27 Million
Market Size 2031USD 4302.83 Million
CAGR 2026-203117.13%
Fastest Growing SegmentDipsticks & Kits
Largest MarketNorth America

However, a significant obstacle to broader market progress is the disparity in diagnostic infrastructure and limited reimbursement frameworks in low-to-middle-income economies, which restricts patient access to essential screening services. This accessibility gap is particularly concerning given the immense disease burden that necessitates effective management strategies. According to the International Society of Nephrology, over 850 million people worldwide were estimated to be affected by kidney disease in 2024, a statistic that underscores the urgent need for scalable and cost-effective testing solutions to mitigate the escalating impact on global health.

Market Driver

The increasing global prevalence of chronic kidney disease (CKD) and the rising incidence of diabetes-related nephropathy are the central forces driving the demand for albumin and creatinine testing. As lifestyle changes lead to higher rates of metabolic disorders, the necessity for routine renal function monitoring has intensified to prevent irreversible organ damage, particularly within diabetic populations where nephropathy is a frequent complication. A report by the Centers for Disease Control and Prevention in May 2024 indicated that approximately one in three adults with diabetes might have chronic kidney disease, highlighting the critical intersection of these conditions and the subsequent need for consistent diagnostic evaluation.

Simultaneously, technological advancements in point-of-care diagnostic solutions and the growing adoption of home-based preventive healthcare monitoring are reshaping market accessibility. Innovations such as smartphone-based urinalysis and high-throughput laboratory systems are removing barriers to testing by offering rapid, user-friendly alternatives to traditional methods. For example, a Healthy.io press release in September 2024 noted that adherence to chronic kidney disease testing more than doubled to a 53.1% completion rate when using a smartphone-enabled home albuminuria test compared to standard care. Furthermore, to address the surging volume of diagnostic requests, companies are enhancing instrument capabilities; Roche's 2024 launch of the cobas c 703 analytical unit, which delivers a throughput of up to 2,000 tests per hour, significantly bolsters laboratory efficiency.

Market Challenge

The primary challenge hindering the growth of the Global Albumin & Creatinine Tests Market is the profound disparity in healthcare infrastructure and reimbursement models, especially within developing economies. While the incidence of renal conditions is rising globally, market expansion is significantly bottlenecked by the inability of healthcare systems in low-to-middle-income countries to fund essential diagnostic tools. Albumin and creatinine tests often remain inaccessible due to limited laboratory capacity and the absence of public funding, which prevents the conversion of the high disease burden into actual diagnostic volume and effectively stalls market penetration in territories that theoretically offer the highest potential volume.

This infrastructural gap creates a direct disconnect between clinical needs and market revenue generation. Without government-backed screening initiatives or insurance coverage, the cost of routine monitoring falls on patients who cannot afford it, leading to widespread under-diagnosis. According to the International Society of Nephrology, in 2024, only 25% of surveyed countries had effectively implemented chronic kidney disease detection programs in their national health policies, severely limiting access to essential urine albumin-to-creatinine ratio testing. Consequently, manufacturers face a ceiling on growth, as the lack of systemic support in these populous regions restricts the adoption of diagnostic reagents and consumables.

Market Trends

The incorporation of Artificial Intelligence for Diagnostic Interpretation is revolutionizing the market by advancing beyond simple automation to predictive risk stratification. Unlike traditional analysis that relies solely on current biomarker levels, new AI models aggregate longitudinal clinical data to forecast renal decline with superior accuracy. According to a September 2025 news release from Carnegie Mellon University, researchers developed a framework combining electronic health records and insurance claims that identified patients progressing to end-stage renal disease with significantly higher precision than standard models over a 24-month observation window.

Concurrently, the market is experiencing a fundamental shift toward combined Albumin-to-Creatinine Ratio assays, driven by evolving clinical frameworks that prioritize this metric over isolated protein testing. This trend is accelerating due to updated global standards mandating ratio-based screening to capture early-stage kidney damage often missed by conventional methods. As reported by the Association for Diagnostics & Laboratory Medicine in July 2025, the 2024 KDIGO guidelines expanded screening protocols by recommending uACR testing for all patients with hypertension, a directive expected to substantially increase assay utilization across clinical settings.

Key Market Players

  • Abbott Laboratories Inc
  • Roche Diagnostics Corp
  • Siemens Healthineers AG
  • Danaher Corp
  • Thermo Fisher Scientific Inc
  • Sysmex Corp
  • Ortho-Clinical Diagnostics, Inc.
  • PromoCell GmbH
  • Randox Laboratories Ltd
  • FUJIFILM Wako Pure Chemical Corp

Report Scope

In this report, the Global Albumin & Creatinine Tests Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Albumin & Creatinine Tests Market, By Product

  • Analyzers
  • Cartridges
  • Dipsticks & Kits
  • Reagents

Albumin & Creatinine Tests Market, By Type

  • Blood & Serum Creatinine Tests
  • Urine Tests

Albumin & Creatinine Tests Market, By End User

  • Hospitals & Clinics
  • Pathologies
  • Research Laboratories & Institutes
  • Others

Albumin & Creatinine Tests Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Albumin & Creatinine Tests Market.

Available Customizations:

Global Albumin & Creatinine Tests Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Albumin & Creatinine Tests Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Analyzers, Cartridges, Dipsticks & Kits, Reagents)
    • 5.2.2. By Type (Blood & Serum Creatinine Tests, Urine Tests)
    • 5.2.3. By End User (Hospitals & Clinics, Pathologies, Research Laboratories & Institutes, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Albumin & Creatinine Tests Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Type
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Albumin & Creatinine Tests Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Type
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Albumin & Creatinine Tests Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Type
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Albumin & Creatinine Tests Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Type
        • 6.3.3.2.3. By End User

7. Europe Albumin & Creatinine Tests Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Type
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Albumin & Creatinine Tests Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Type
        • 7.3.1.2.3. By End User
    • 7.3.2. France Albumin & Creatinine Tests Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Type
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Albumin & Creatinine Tests Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Type
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Albumin & Creatinine Tests Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Type
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Albumin & Creatinine Tests Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Type
        • 7.3.5.2.3. By End User

8. Asia Pacific Albumin & Creatinine Tests Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Type
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Albumin & Creatinine Tests Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Type
        • 8.3.1.2.3. By End User
    • 8.3.2. India Albumin & Creatinine Tests Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Type
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Albumin & Creatinine Tests Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Type
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Albumin & Creatinine Tests Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Type
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Albumin & Creatinine Tests Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Type
        • 8.3.5.2.3. By End User

9. Middle East & Africa Albumin & Creatinine Tests Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Type
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Albumin & Creatinine Tests Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Type
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Albumin & Creatinine Tests Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Type
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Albumin & Creatinine Tests Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Type
        • 9.3.3.2.3. By End User

10. South America Albumin & Creatinine Tests Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Type
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Albumin & Creatinine Tests Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Type
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Albumin & Creatinine Tests Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Type
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Albumin & Creatinine Tests Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Type
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Albumin & Creatinine Tests Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Abbott Laboratories Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Roche Diagnostics Corp
  • 15.3. Siemens Healthineers AG
  • 15.4. Danaher Corp
  • 15.5. Thermo Fisher Scientific Inc
  • 15.6. Sysmex Corp
  • 15.7. Ortho-Clinical Diagnostics, Inc.
  • 15.8. PromoCell GmbH
  • 15.9. Randox Laboratories Ltd
  • 15.10. FUJIFILM Wako Pure Chemical Corp

16. Strategic Recommendations

17. About Us & Disclaimer